To elucidate the downstream signalling pathways mediated by PAX5 in tumour inhibition, we performed semi‐quantitative PCR and Western blot to evaluate the expression of components of the β‐catenin signalling pathways. The gene discussed is PAX5; the disease is neoplasm.